Acadia Pharmaceutica (ACAD)

$24.02 +0.38 (1.61%)
Market Cap 4.08B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 33.89
Forward PE 35.35
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 1,236,855
Avg Vol 2,113,012
Day's Range N/A - N/A
Shares Out 169.18M
Stochastic %K 80%
Beta 0.80
Analysts Strong Sell
Price Target $29.42

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 212 0513
Address:
12830 El Camino Real, Suite 400, San Diego, United States
zeustony88
zeustony88 Nov. 14 at 7:14 PM
$ACAD RTW Investing buying 7 mil shares
0 · Reply
Quantumup
Quantumup Nov. 14 at 12:45 PM
Cantor reit $TSHA OW13 $NGNE $ACAD Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha's TSHA-102 (intrathecally administered AAV9-based gene therapy). NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE's release. While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don't fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a "responder" in their pivotal trial.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:52 AM
$ACAD is currently trading at $23.64, showing a bullish sentiment as indicated by an RSI of 60.95, suggesting upward momentum but nearing overbought conditions. The price is above the 30-day moving average (MA30) of 21.87 and the 50-day moving average (MA50) of 22.44, reinforcing a positive trend. The recent high of 26.65 indicates potential resistance, while the low of 19.69 provides a support level. Directional bias is bullish, supported by the price action above key moving averages and the RSI indicating strength. Suggested entry is at $23.70, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological level, and Target 2 is $26.00, just below the recent high. This trade plan capitalizes on the current upward momentum while maintaining a clear risk management strategy. https://privateprofiteers.com
0 · Reply
zeustony88
zeustony88 Nov. 13 at 4:05 PM
$ACAD $25 plus.......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:59 AM
$ACAD is currently trading at $23.72, showing a strong upward momentum with an RSI of 66.34, indicating it is nearing overbought territory. The stock is above its 30-day moving average (MA30) of 21.69 and its 50-day moving average (MA50) of 22.51, suggesting a bullish trend. However, the RSI indicates caution as it approaches overbought levels. Given the 60-day high of 26.65, there is potential for further upside, but the current price is also close to the 60-day low of 19.69, indicating volatility. Suggested entry is at $23.50, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological resistance level, and Target 2 is $26.00, approaching the recent high. Overall, maintain a bullish bias while being aware of potential pullbacks due to the RSI level. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 10:11 PM
UBS updates rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy, target set at 27 → 25.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:35 AM
$ACAD is currently trading at $23.72, showing a strong upward momentum with an RSI of 66.34, indicating it is nearing overbought territory. The stock is above its 30-day moving average (MA30) of 21.69 and its 50-day moving average (MA50) of 22.51, suggesting a bullish trend. However, the RSI indicates caution as it approaches overbought levels. Given the 60-day high of 26.65, there is potential for further upside, but the current price is also close to the 60-day low of 19.69, indicating volatility. Suggested entry is at $23.50, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological resistance level, and Target 2 is $26.00, approaching the recent high. Overall, maintain a bullish bias while being aware of potential pullbacks due to the RSI level. https://privateprofiteers.com
0 · Reply
LoganFive
LoganFive Nov. 11 at 8:48 PM
$ACAD Nice 👍🏻
0 · Reply
BullMaven
BullMaven Nov. 10 at 7:44 PM
$ACAD
0 · Reply
raylin
raylin Nov. 7 at 10:58 PM
$ACAD BS beatdown early and strong recovery late!
0 · Reply
Latest News on ACAD
ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:31 PM EST - 4 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents at UBS Global Healthcare Conference 2025 Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:36 AM EST - 8 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Nov 5, 2025, 4:05 PM EST - 9 days ago

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Oct 28, 2025, 4:05 PM EDT - 17 days ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 3:41 PM EDT - 23 days ago

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 15, 2025, 4:05 PM EDT - 4 weeks ago

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Oct 6, 2025, 7:30 AM EDT - 5 weeks ago

ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2025, 9:04 AM EDT - 6 weeks ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Sep 24, 2025, 10:05 AM EDT - 7 weeks ago

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Sep 24, 2025, 7:12 AM EDT - 7 weeks ago

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Sep 24, 2025, 7:00 AM EDT - 7 weeks ago

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Sep 12, 2025, 4:05 PM EDT - 2 months ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:04 PM EDT - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 25, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:57 AM EDT - 3 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 6, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Aug 4, 2025, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 3 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jul 23, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 9, 2025, 4:01 PM EDT - 5 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Jun 5, 2025, 9:05 AM EDT - 5 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 6 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 6 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 16, 2025, 1:43 PM EDT - 6 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 6 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 8:10 PM EDT - 6 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 7, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 5, 2025, 4:05 PM EDT - 6 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 4:05 PM EDT - 7 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 5, 2025, 9:05 AM EST - 9 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 3, 2025, 9:05 AM EST - 9 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 9 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:13 PM EST - 9 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 26, 2025, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 9 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:05 AM EST - 10 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Jan 14, 2025, 9:00 AM EST - 10 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 19, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 11, 2024, 4:05 PM EST - 1 year ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Dec 9, 2024, 9:00 AM EST - 1 year ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 27, 2024, 3:18 PM EST - 1 year ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 26, 2024, 4:05 PM EST - 1 year ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 11, 2024, 10:50 AM EST - 1 year ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

zeustony88
zeustony88 Nov. 14 at 7:14 PM
$ACAD RTW Investing buying 7 mil shares
0 · Reply
Quantumup
Quantumup Nov. 14 at 12:45 PM
Cantor reit $TSHA OW13 $NGNE $ACAD Neurogene (NGNE, NC) reported updated Phase 1/2 data for its ICV-administered gene therapy NGN-401 in Rett syndrome (rare neurodevelopmental disorder). From our conversations, we believe investors have spent more time focusing on key differences between the approaches, although there have also been questions about how to interpret cross-data comparisons with Taysha's TSHA-102 (intrathecally administered AAV9-based gene therapy). NGNE shares closed -15% today (vs. -8% for TSHA), which we believe could be in part related to some of the treatment-related AEs that were disclosed in NGNE's release. While we believe both companies are assessing natural history datasets to understand what is deemed a milestone, skill, etc., we don't fully appreciate or understand what analysis NGNE evaluated their data against. Nor do we fully understand the statistical analysis plan NGNE has put into place to fully appreciate what is deemed a "responder" in their pivotal trial.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:52 AM
$ACAD is currently trading at $23.64, showing a bullish sentiment as indicated by an RSI of 60.95, suggesting upward momentum but nearing overbought conditions. The price is above the 30-day moving average (MA30) of 21.87 and the 50-day moving average (MA50) of 22.44, reinforcing a positive trend. The recent high of 26.65 indicates potential resistance, while the low of 19.69 provides a support level. Directional bias is bullish, supported by the price action above key moving averages and the RSI indicating strength. Suggested entry is at $23.70, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological level, and Target 2 is $26.00, just below the recent high. This trade plan capitalizes on the current upward momentum while maintaining a clear risk management strategy. https://privateprofiteers.com
0 · Reply
zeustony88
zeustony88 Nov. 13 at 4:05 PM
$ACAD $25 plus.......
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:59 AM
$ACAD is currently trading at $23.72, showing a strong upward momentum with an RSI of 66.34, indicating it is nearing overbought territory. The stock is above its 30-day moving average (MA30) of 21.69 and its 50-day moving average (MA50) of 22.51, suggesting a bullish trend. However, the RSI indicates caution as it approaches overbought levels. Given the 60-day high of 26.65, there is potential for further upside, but the current price is also close to the 60-day low of 19.69, indicating volatility. Suggested entry is at $23.50, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological resistance level, and Target 2 is $26.00, approaching the recent high. Overall, maintain a bullish bias while being aware of potential pullbacks due to the RSI level. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 10:11 PM
UBS updates rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy, target set at 27 → 25.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:35 AM
$ACAD is currently trading at $23.72, showing a strong upward momentum with an RSI of 66.34, indicating it is nearing overbought territory. The stock is above its 30-day moving average (MA30) of 21.69 and its 50-day moving average (MA50) of 22.51, suggesting a bullish trend. However, the RSI indicates caution as it approaches overbought levels. Given the 60-day high of 26.65, there is potential for further upside, but the current price is also close to the 60-day low of 19.69, indicating volatility. Suggested entry is at $23.50, with a stop loss set at $22.50 to manage risk. Target 1 is $25.00, aligning with a psychological resistance level, and Target 2 is $26.00, approaching the recent high. Overall, maintain a bullish bias while being aware of potential pullbacks due to the RSI level. https://privateprofiteers.com
0 · Reply
LoganFive
LoganFive Nov. 11 at 8:48 PM
$ACAD Nice 👍🏻
0 · Reply
BullMaven
BullMaven Nov. 10 at 7:44 PM
$ACAD
0 · Reply
raylin
raylin Nov. 7 at 10:58 PM
$ACAD BS beatdown early and strong recovery late!
0 · Reply
zeustony88
zeustony88 Nov. 7 at 7:25 PM
$ACAD Why the drop yesterday?
0 · Reply
BullMaven
BullMaven Nov. 7 at 6:41 PM
$ACAD
0 · Reply
zeustony88
zeustony88 Nov. 7 at 2:44 PM
$ACAD Wake me up in 2026 with ADP. The only thing that's gonna move this
1 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 5:53 PM
$ACAD just crushed Q3 — double-digit revenue growth powered by Nuplazid & Daybue 💥 Earnings and revenues topped forecasts, showing strong momentum across both key products. Full breakdown of the beat here 👉 https://www.zacks.com/stock/news/2787031/acad-q3-earnings-beat-nuplazid-daybue-drive-yy-revenue-growth?cid=sm-stocktwits-2-2787031-teaser-19882&ADID=SYND_STOCKTWITS_TWEET_2_2787031_TEASER_19882
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 4:53 PM
$ACAD beats Q3 earnings with a strong show! 🚀 🎯 EPS of 26 cents (excluding one-time tax benefit) crushes Zacks Consensus of 14 cents 📈 Total revenues jump 11% YoY, driven by Nuplazid & Daybue growth 💰 Shares up 21.7% YTD, outpacing the industry’s 10.2% rise Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2787031/acad-q3-earnings-beat-nuplazid-daybue-drive-yy-revenue-growth?cid=sm-stocktwits-2-2787031-body-19868&ADID=SYND_STOCKTWITS_TWEET_2_2787031_BODY_19868
0 · Reply
ZacksResearch
ZacksResearch Nov. 6 at 3:54 PM
$RXRX plunges 26.7% YTD — is the biotech sector leaving it behind? Despite a narrower-than-expected Q3 loss, revenue fell short of estimates, though the company's strategic pipeline shifts focus on more promising candidates. Meanwhile, other biotech stocks like $ANIP (Rank #2) and $ACAD (Rank #2) are showing stronger Zacks Ranks and earnings momentum. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2786757/rxrx-q3-loss-narrower-than-expected-revenues-decline-yy?cid=sm-stocktwits-2-2786757-body-19838&ADID=SYND_STOCKTWITS_TWEET_2_2786757_BODY_19838
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 3:35 PM
RBC Capital updates rating for ACADIA Pharmaceuticals ( $ACAD ) to Outperform, target set at 34 → 32.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 10:07 AM
Needham has updated their rating for ACADIA Pharmaceuticals ( $ACAD ) to Buy with a price target of 29.
0 · Reply
shortkiller7
shortkiller7 Nov. 6 at 9:03 AM
$ACAD When is the reverse split? When does the patent expire? When is another dillutive offering? When is bankruptcy? 2
1 · Reply
shortkiller7
shortkiller7 Nov. 6 at 5:39 AM
$ACAD When is the reverse split? When does the patent expire? When is another dillutive offering? When is bankruptcy?
0 · Reply
Ham1198
Ham1198 Nov. 5 at 11:01 PM
$ACAD Not bad quarter. What does SP do tomorrow?????
2 · Reply
raylin
raylin Nov. 5 at 10:34 PM
$ACAD Only heard most of the QA but it was good.
0 · Reply